Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

[1]  David B Solit,et al.  Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response , 2010, Clinical Cancer Research.

[2]  Michael Krauthammer,et al.  PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.

[3]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Carlo Gambacorti-Passerini,et al.  BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells , 2008, Molecular Cancer Research.

[5]  D. Demetrick,et al.  BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. , 2009, Archives of pathology & laboratory medicine.

[6]  P. Gimotty,et al.  Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. , 2007, The Journal of molecular diagnostics : JMD.

[7]  D. Schadendorf,et al.  B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis , 2007, PloS one.

[8]  Stephen B Gruber,et al.  BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.

[9]  S. Tripp,et al.  Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.

[10]  I. Wistuba,et al.  BRAF Mutation: A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin , 2003, The American Journal of dermatopathology.